COGT Stock Up 67% after 11-Day Win Streak

COGT: Cogent Biosciences logo
COGT
Cogent Biosciences

Cogent Biosciences (COGT) stock hit day 11 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 67% return. The company has gained about $842 Mil in value over the last 11 days, with its current market capitalization at about $1.3 Bil. The stock remains 52.1% above its value at the end of 2024. This compares with year-to-date returns of 6.5% for the S&P 500.

Comparing COGT Stock Returns With The S&P 500

The following table summarizes the return for COGT stock vs. the S&P 500 index over different periods, including the current streak:

Return Period COGT S&P 500
1D 3.1% 0.3%
11D (Current Streak) 67.0% 1.5%
1M (21D) 64.3% 3.6%
3M (63D) 178.4% 16.8%
YTD 2025 52.1% 6.5%
2024 32.7% 23.3%
2023 -49.1% 24.2%
2022 34.7% -19.4%

Gains and Losses Streaks: S&P 500 Constituents

There are currently 17 S&P constituents with 3 days or more of consecutive gains and 66 constituents with 3 days or more of consecutive losses.

Consecutive Days # of Gainers # of Losers
3D 13 22
4D 0 35
5D 0 3
6D 3 5
7D or more 1 1
Total >=3 D 17 66

 

Relevant Articles
  1. Is Qualcomm Stock A Bet On AI’s Future Or A Hostage To The Smartphone’s Present?
  2. The Quiet Contract Shift Before Western Digital Stock’s Loud Re-Rating
  3. Beyond the Quarter: What Could Power The Next Leg Of Broadcom Stock’s Climb
  4. Booking Stock Testing Price Floor – Buy Now?
  5. Ciena’s AI Story Is Soaring. Is Ubiquiti The Smarter Play?
  6. Flex’s AI Story Is Soaring. Is TE Connectivity The Wiser Bet?

Key Financials for Cogent Biosciences (COGT)

Last 2 Fiscal Years:

Metric FY2023 FY2024
Revenues $- $-
Operating Income $-208.1 Mil $-275.9 Mil
Net Income $-192.4 Mil $-255.9 Mil

Last 2 Fiscal Quarters:

Metric 2024 FQ4 2025 FQ1
Revenues $- $-
Operating Income $-73.7 Mil $-74.9 Mil
Net Income $-67.9 Mil $-72.0 Mil

While COGT stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.